ClinicalTrials.gg
CompletedNCT00624780Updated Jan 28, 2021Results posted

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

A Phase 4 interventional study of Pregabalin and Lorazepam in Generalized Anxiety Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 57 sites in 16 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
615
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).

02

Conditions studied

  • Generalized Anxiety Disorder
03

In context

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

This study's enrollment of 615 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis Generalized Anxiety Disorder
  • HAM-A score >=18 and HAM-D (item 1) score >=2 at screening and baseline
  • Needs pharmacological treatment

Exclusion criteria

Exclusion Criteria:

  • Current or past diagnosis of any other DSM IV Axis I disorders
  • A history of failed treatment with a benzodiazepine
  • Any , serious, or unstable hematologic, , endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
615 participants (actual)

Study arms

  • Experimental
    1

    Drug: Pregabalin

  • Active comparator
    2

    Drug: Lorazepam

  • Experimental
    3

    Drug: Pregabalin

  • Placebo comparator
    4

    Drug: Placebo

Interventions

  • Pregabalin 150-300 mg given twice a day

    Also known as: Lyrica

  • Lorazepam 3-4 mg given twice a day

  • Pregabalin 450-600 mg given twice a day

    Also known as: Lyrica

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  2. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  3. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  4. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  5. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

  6. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

  7. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  8. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  9. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  10. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  11. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

  12. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

Secondary outcomes

  1. Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)

    Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.

    Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)

  2. Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)

    Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.

    Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  3. Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)

    Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.

    Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

  4. Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 1 (Less Than 3-Month Last Visit)

    DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.

    Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)

  5. Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 2 (3-Month Last Visit)

    DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.

    Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  6. Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 3 (6-Month Last Visit)

    DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.

    Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

  7. Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  8. Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  9. Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)

  10. Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit)

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  11. Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit)

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  12. Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit)

    PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

  13. Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  14. Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.

    Time frame: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  15. Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)

  16. Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit)

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)

  17. Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit)

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.

    Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)

  18. Hamilton Anxiety Scale (HAM-A) Score for Cohort 3 (6-Month Last Visit)

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)

  19. Hamilton Anxiety Scale (HAM-A) Score for Period 1

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 12

  20. Hamilton Anxiety Scale (HAM-A) Score for Period 2

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 24

  21. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 12

  22. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24

    HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

    Time frame: Baseline, Week 24

  23. Clinical Global Impression - Severity (CGI-S) Score for Period 1

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

    Time frame: Baseline, Week 12

  24. Clinical Global Impression - Severity (CGI-S) Score for Period 2

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected

    Time frame: Baseline, Week 24

  25. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

    Time frame: Baseline, Week 12

  26. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected

    Time frame: Baseline, Week 24

  27. Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 1

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.

    Time frame: Week 12

  28. Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 2

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.

    Time frame: Week 24

Other outcomes

  1. Sheehan-Suicidality Tracking Scale (S-STS) Score

    Sheehan-Suicidality Tracking Scale (S-STS): an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2-6, 7a, and 8 were scored on a 5-point Likert scale (ranging from 0= not at all to 4=extremely). Items 1, 1b, and 7 required yes or no responses. Total score ranged from 0 to 35, higher score indicated higher suicidal tendency.

    Time frame: Baseline up to Week 24

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and Week 12, for period 1, and between Week 13 and Week 24, for period 2, that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to Week 12 (period 1), Week 13 up to Week 24 (period 2)

07

Results

Posted Apr 19, 2013

Participant flow

Treatment Optimization (Up to Week 12)
Participant flow — Treatment Optimization (Up to Week 12)
MilestonePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Started154521545215350
Completed121391123811439
Not completed331342143911
Withdrew: Adverse event7515395
Withdrew: Lack of efficacy5210591
Withdrew: Lost to follow-up102021
Withdrew: Withdrawal by subject10274104
Withdrew: Other1048290
Fixed Dosing (Week 13 to Week 24)
Participant flow — Fixed Dosing (Week 13 to Week 24)
MilestonePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Started121391123811439
Completed1062894279530
Not completed15111811199
Withdrew: Adverse event545231
Withdrew: Lack of efficacy212552
Withdrew: Lost to follow-up101011
Withdrew: Withdrawal by subject236362
Withdrew: Other534143
Treatment Discontinuation (Week 25)
Participant flow — Treatment Discontinuation (Week 25)
MilestonePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Started1062894279530
Completed1042891269529
Not completed203101
Withdrew: Adverse event102101
Withdrew: Lack of efficacy100000
Withdrew: Lost to follow-up001000
Follow-up (Week 26)
Participant flow — Follow-up (Week 26)
MilestonePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Started1042891269529
Completed1022789269329
Not completed212020
Withdrew: Death001000
Withdrew: Adverse event000010
Withdrew: Lost to follow-up001010
Withdrew: Withdrawal by subject100000
Withdrew: Other110000

Outcome measures

PrimaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Baseline (n=15,19,21)25.8 ± 4.2324.9 ± 4.1524.4 ± 4.88
Change at Discontinuation Week 1 (n=15,19,18)-7.7 ± 6.75-5.9 ± 7.20-9.9 ± 10.81
PrimaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2-12.0 ± 7.24-5.9 ± 5.46-9.7 ± 11.08
PrimaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Baseline25.0 ± 5.3724.7 ± 3.8924.6 ± 4.76
Change at Discontinuation Week 1-15.3 ± 7.76-15.3 ± 6.71-15.8 ± 7.92
PrimaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2-15.6 ± 7.42-14.9 ± 7.11-16.0 ± 7.96
PrimaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Baseline25.5 ± 3.8524.2 ± 4.6424.7 ± 3.8524.9 ± 3.8224.6 ± 4.3624.9 ± 3.93
Change at Discontinuation Week 1-17.6 ± 7.25-18.7 ± 5.36-18.4 ± 6.33-16.5 ± 7.25-16.2 ± 8.11-19.1 ± 6.69
PrimaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2-16.6 ± 8.53-19.1 ± 5.80-18.3 ± 7.05-16.0 ± 8.17-16.7 ± 7.52-18.7 ± 7.38
PrimaryChange From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Last visit on treatment (n=15,18,20)10.1 ± 8.7216.8 ± 13.2013.1 ± 10.75
Change at Discontinuation Week 1 (n=15,18,18)0.1 ± 9.89-2.8 ± 7.99-4.2 ± 6.12
PrimaryChange From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2-2.0 ± 6.39-2.7 ± 9.04-3.2 ± 6.05
PrimaryChange From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Last visit on treatment7.2 ± 7.326.5 ± 6.015.0 ± 3.80
Change at Discontinuation Week 11.9 ± 7.291.4 ± 4.522.3 ± 6.60
PrimaryChange From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 22.1 ± 6.112.0 ± 5.511.6 ± 6.33
PrimaryChange From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Last visit on treatment5.2 ± 5.624.9 ± 7.153.9 ± 4.146.5 ± 6.725.3 ± 6.654.7 ± 4.50
Change at Discontinuation Week 11.7 ± 4.920.0 ± 2.181.1 ± 3.501.0 ± 4.373.0 ± 6.79-0.1 ± 3.22
PrimaryChange From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 22.8 ± 5.99-1.0 ± 5.651.7 ± 4.781.8 ± 5.142.2 ± 6.02-0.1 ± 3.63
SecondaryNumber of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)

Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.

Time frame:
2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Number · participants
Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)
participantsPregabalin High DosePregabalin Low DoseLorazepam
Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)151
SecondaryNumber of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)

Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.

Time frame:
2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Number · participants
Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)
participantsPregabalin High DosePregabalin Low DoseLorazepam
Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)312
SecondaryNumber of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)

Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.

Time frame:
2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Number · participants
Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)
participantsPregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)400160
SecondaryNumber of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 1 (Less Than 3-Month Last Visit)

DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.

Time frame:
2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Number · participants
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 1 (Less Than 3-Month Last Visit)
participantsPregabalin High DosePregabalin Low DoseLorazepam
Newly developed DESS603
Worsened DESS000
SecondaryNumber of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 2 (3-Month Last Visit)

DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.

Time frame:
2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Number · participants
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 2 (3-Month Last Visit)
participantsPregabalin High DosePregabalin Low DoseLorazepam
Newly developed DESS403836
Worsened DESS121
SecondaryNumber of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 3 (6-Month Last Visit)

DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.

Time frame:
2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Number · participants
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 3 (6-Month Last Visit)
participantsPregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Newly developed DESS7853517507
Worsened DESS202150
SecondaryChange From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Baseline (n=14,19,21)13.6 ± 8.1917.6 ± 10.6816.4 ± 8.62
Change at Discontinuation Week 1 (n=14,19,18)-3.4 ± 11.91-3.3 ± 9.12-5.9 ± 7.43
Change at Discontinuation Week 2 (n=13,15,16)-4.7 ± 10.62-2.7 ± 8.20-5.4 ± 8.34
SecondaryChange From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Baseline (n=57,51,52)17.4 ± 7.8117.1 ± 9.8414.8 ± 7.86
Change at Discontinuation Week 1 (n=57,51,49)-8.5 ± 9.40-9.3 ± 9.48-7.6 ± 9.53
Change at Discontinuation Week 2 (n=53,48,44)-8.3 ± 9.53-8.7 ± 9.68-8.0 ± 9.70
SecondaryChange From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Baseline, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Baseline (n=109,30,94,29,99,30)17.8 ± 8.3617.8 ± 7.7916.1 ± 7.5217.4 ± 9.2816.8 ± 8.8514.9 ± 7.61
Change at DC Week 1 (n=109,30,94,29,99,30)-11.0 ± 9.48-12.9 ± 7.89-11.0 ± 8.08-9.9 ± 10.98-8.7 ± 10.77-10.4 ± 7.58
Change at DC Week 2 (n=106,29,84,26,92,30)-9.8 ± 10.32-13.8 ± 8.32-10.8 ± 8.42-10.2 ± 8.56-9.6 ± 9.70-10.3 ± 7.50
SecondaryPhysician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit)

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit)
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Discontinuation Week 1 (n=15,19,18)10.2 ± 7.9714.3 ± 10.049.1 ± 9.25
Discontinuation Week 2 (n=14,15,16)8.2 ± 6.7014.1 ± 9.1610.6 ± 9.39
SecondaryPhysician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit)

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit)
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Discontinuation Week 1 (n=58,52,49)9.1 ± 6.828.0 ± 6.197.3 ± 6.69
Discontinuation Week 2 (n=54,49,44)8.9 ± 7.288.3 ± 6.326.9 ± 6.38
SecondaryPhysician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit)

PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Week 1, 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit)
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Discontinuation Week 1 (n=109,30,94,29,99,30)6.8 ± 6.564.9 ± 5.735.1 ± 4.457.4 ± 6.438.0 ± 7.454.6 ± 4.22
Discontinuation Week 2 (n=106,29,84,26,93,30)7.9 ± 7.594.1 ± 4.175.7 ± 6.117.1 ± 8.657.1 ± 6.644.6 ± 4.67
SecondaryChange From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Last visit on treatment (n=15,18,20)16.1 ± 8.4621.6 ± 6.1816.1 ± 10.11
Change at Discontinuation Week 1 (n=15,18,18)2.0 ± 11.45-2.3 ± 4.63-2.4 ± 3.31
Change at Discontinuation Week 2 (n=14,15,16)-2.3 ± 9.47-3.5 ± 5.34-2.2 ± 4.18
SecondaryChange From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.

Time frame:
Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Last visit on treatment (n=58,52,50)8.0 ± 6.578.5 ± 6.506.7 ± 4.29
Change at Discontinuation Week 1 (n=58,52,48)1.7 ± 6.690.9 ± 4.032.3 ± 5.74
Change at Discontinuation Week 2 (n=54,49,44)1.5 ± 5.551.5 ± 6.431.5 ± 5.37
SecondaryChange From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Last visit on treatment (n=109,30,93,29,100,30)6.3 ± 5.895.5 ± 6.125.6 ± 5.028.3 ± 6.495.6 ± 6.175.5 ± 4.66
Change at DC Week 1 (n=109,30,93,28,99,30)1.6 ± 4.37-0.0 ± 2.300.7 ± 3.080.6 ± 2.693.0 ± 5.730.3 ± 3.01
Change at DC Week 2 (n=107,29,84,26,94,30)2.5 ± 5.74-0.8 ± 5.331.2 ± 3.901.5 ± 5.082.2 ± 5.390.6 ± 3.76
SecondaryHamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit)

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Reported as:
Mean · units on a scale
Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit)
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Discontinuation Week 1 (n=15,19,18)18.1 ± 7.1119.0 ± 7.6114.1 ± 10.31
Discontinuation Week 2 (n=14,15,16)13.9 ± 7.3318.6 ± 6.1514.6 ± 10.41
SecondaryHamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit)

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.

Time frame:
Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Reported as:
Mean · units on a scale
Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit)
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Discontinuation Week 1 (n=58,52,48)9.6 ± 6.389.4 ± 6.608.8 ± 5.88
Discontinuation Week 2 (n=54,49,44)9.0 ± 6.449.9 ± 7.048.3 ± 6.48
SecondaryHamilton Anxiety Scale (HAM-A) Score for Cohort 3 (6-Month Last Visit)

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
Reported as:
Mean · units on a scale
Hamilton Anxiety Scale (HAM-A) Score for Cohort 3 (6-Month Last Visit)
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Discontinuation Week 1 (n=109,30,94,28,99,30)7.9 ± 6.345.5 ± 4.856.3 ± 5.488.4 ± 6.678.4 ± 7.077.07 ± 4.92
Discontinuation Week 2 (n=107,29,84,26,94,30)8.9 ± 7.605.0 ± 4.326.5 ± 6.369.2 ± 8.287.9 ± 6.276.1 ± 6.00
SecondaryHamilton Anxiety Scale (HAM-A) Score for Period 1

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Hamilton Anxiety Scale (HAM-A) Score for Period 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Baseline25.3 ± 4.3924.9 ± 3.8724.5 ± 4.39
Week 128.0 ± 6.238.9 ± 7.197.9 ± 6.70
SecondaryHamilton Anxiety Scale (HAM-A) Score for Period 2

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Hamilton Anxiety Scale (HAM-A) Score for Period 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Baseline25.6 ± 3.8224.6 ± 4.6624.8 ± 3.7725.1 ± 3.9224.7 ± 4.4124.1 ± 4.03
Week 247.0 ± 6.537.1 ± 7.096.5 ± 5.9810.2 ± 7.495.7 ± 6.066.6 ± 6.33
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12-17.4 ± 7.39-16.0 ± 7.45-16.7 ± 7.92
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24

HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24-18.7 ± 7.33-17.5 ± 6.89-18.2 ± 6.59-14.9 ± 7.85-19.0 ± 7.24-17.5 ± 8.34
SecondaryClinical Global Impression - Severity (CGI-S) Score for Period 1

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Clinical Global Impression - Severity (CGI-S) Score for Period 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Baseline4.6 ± 0.684.5 ± 0.714.4 ± 0.65
Week 122.3 ± 1.062.5 ± 1.172.3 ± 1.00
SecondaryClinical Global Impression - Severity (CGI-S) Score for Period 2

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Clinical Global Impression - Severity (CGI-S) Score for Period 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Baseline4.7 ± 0.654.5 ± 0.694.5 ± 0.714.5 ± 0.734.4 ± 0.684.5 ± 0.56
Week 242.3 ± 1.082.2 ± 1.162.1 ± 0.972.5 ± 1.241.9 ± 0.902.4 ± 0.98
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12-2.3 ± 1.13-2.1 ± 1.13-2.1 ± 1.17
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24-2.4 ± 1.13-2.3 ± 1.24-2.4 ± 1.04-2.0 ± 1.27-2.5 ± 1.11-2.2 ± 1.17
SecondaryClinical Global Impression - Improvement (CGI-I) Score at the End of Period 1

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 1
units on a scalePregabalin High DosePregabalin Low DoseLorazepam
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 11.9 ± 1.131.9 ± 1.011.9 ± 1.17
SecondaryClinical Global Impression - Improvement (CGI-I) Score at the End of Period 2

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.

Time frame:
Week 24
Reported as:
Mean · units on a scale
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 2
units on a scalePregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 21.7 ± 0.991.9 ± 1.151.6 ± 0.752.3 ± 1.531.5 ± 0.912.0 ± 1.07
Other pre-specifiedSheehan-Suicidality Tracking Scale (S-STS) Score

Sheehan-Suicidality Tracking Scale (S-STS): an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2-6, 7a, and 8 were scored on a 5-point Likert scale (ranging from 0= not at all to 4=extremely). Items 1, 1b, and 7 required yes or no responses. Total score ranged from 0 to 35, higher score indicated higher suicidal tendency.

Time frame:
Baseline up to Week 24

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and Week 12, for period 1, and between Week 13 and Week 24, for period 2, that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to Week 12 (period 1), Week 13 up to Week 24 (period 2)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
participantsPregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Period 1 (n=154,52,154,52,153,50)10337100409535
Period 2 (n=121,39,112,38,114,39)622662185220

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin High Dose, Pregabalin High Dose—2/154 (1.3%)110/154 (71.4%)
Pregabalin High Dose, Placebo—0/52 (0%)40/52 (76.9%)
Pregabalin Low Dose, Pregabalin Low Dose—5/154 (3.2%)108/154 (70.1%)
Pregabalin Low Dose, Placebo—2/52 (3.8%)38/52 (73.1%)
Lorazepam, Lorazepam—4/153 (2.6%)100/153 (65.4%)
Lorazepam, Placebo—0/50 (0%)35/50 (70%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
Abdominal herniaGastrointestinal disorders0/1540/520/1541/520/1530/50
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/1540/520/1541/520/1530/50
HyperglycaemiaMetabolism and nutrition disorders0/1540/520/1541/520/1530/50
KetoacidosisMetabolism and nutrition disorders0/1540/520/1541/520/1530/50
Myocardial infarctionCardiac disorders0/1540/520/1540/521/1530/50
Myocardial ischaemiaCardiac disorders0/1540/520/1540/521/1530/50
Food poisoningGastrointestinal disorders0/1540/520/1540/521/1530/50
Typhoid feverInfections and infestations0/1540/520/1540/521/1530/50
Generalised anxiety disorderPsychiatric disorders0/1540/521/1540/521/1530/50
Inguinal herniaGastrointestinal disorders0/1540/521/1540/520/1530/50
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, Placebo
DizzinessNervous system disorders37/15417/5228/15414/5220/15310/50
HeadacheNervous system disorders38/15413/5236/15417/5233/15310/50
InsomniaPsychiatric disorders31/15415/5224/15412/5223/15313/50
SomnolenceNervous system disorders25/1547/5231/1549/5235/15313/50
FatigueGeneral disorders16/1546/5215/15411/5215/1535/50
NauseaGastrointestinal disorders17/1547/5212/1548/5218/1537/50
AnxietyPsychiatric disorders14/1546/5210/1541/5219/1535/50
DiarrhoeaGastrointestinal disorders10/1543/528/1545/529/1531/50
NasopharyngitisInfections and infestations13/1542/527/1545/528/1534/50
Dry mouthGastrointestinal disorders13/1543/525/1542/528/1534/50

Baseline characteristics

Age, Customized
Age, Customized(participants)Pregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, PlaceboTotal
18 to 44 years7530100288627346
45 to 64 years792251246623265
Greater than or equal to 65 years0030104
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin High Dose, Pregabalin High DosePregabalin High Dose, PlaceboPregabalin Low Dose, Pregabalin Low DosePregabalin Low Dose, PlaceboLorazepam, LorazepamLorazepam, PlaceboTotal
Female8930101329527374
Male652253205823241
08

Study locations

57 sites
  • Pfizer Investigational Site
    La Plata, Buenos Aires B1904ADM, Argentina
  • Pfizer Investigational Site
    Lanus, Prov. De Buenos Aires B1824IBR, Argentina
  • Pfizer Investigational Site
    Buenos Aires, C1115AAJ, Argentina
  • Pfizer Investigational Site
    Buenos Aires, C1405BOA, Argentina
  • Pfizer Investigational Site
    Buenos Aires, C1428AQK, Argentina
  • Pfizer Investigational Site
    Wien, A-1010, Austria
  • Pfizer Investigational Site
    Wien, A-1090, Austria
  • Pfizer Investigational Site
    San Jose, 00000, Costa Rica
  • Pfizer Investigational Site
    San Jose, Costa Rica
  • Pfizer Investigational Site
    Rijeka, 51000, Croatia
  • Pfizer Investigational Site
    Split, 21000, Croatia
  • Pfizer Investigational Site
    Zagreb, 10000, Croatia
  • Pfizer Investigational Site
    Brno, 602 00, Czechia
  • Pfizer Investigational Site
    Ceske Budejovice, 370 87, Czechia
  • Pfizer Investigational Site
    Litomerice, 412 01, Czechia
  • Pfizer Investigational Site
    Lnare, 387 42, Czechia
  • Pfizer Investigational Site
    Melnik, 276 01, Czechia
  • Pfizer Investigational Site
    Praha 10- Strasnice, 10000, Czechia
  • Pfizer Investigational Site
    Praha 2, 120 00, Czechia
  • Pfizer Investigational Site
    Praha 6, 160 00, Czechia
  • Pfizer Investigational Site
    Strakonice, 386 01, Czechia
  • Pfizer Investigational Site
    Espoo, 02650, Finland
  • Pfizer Investigational Site
    HUS, 00029, Finland
  • Pfizer Investigational Site
    Joensuu, 80100, Finland
  • Pfizer Investigational Site
    Kuopio, 70110, Finland
  • Pfizer Investigational Site
    Seinajoki, 60100, Finland
  • Pfizer Investigational Site
    Turku, 20100, Finland
  • Pfizer Investigational Site
    Athens, 11528, Greece
  • Pfizer Investigational Site
    Ellisbridge, Ahmedabad 380 006, India
  • Pfizer Investigational Site
    Tirupati, Andhra Pradesh 517 507, India
  • Pfizer Investigational Site
    Mangalore, Karnataka 575001, India
  • Pfizer Investigational Site
    Pune, Maharashtra 411 030, India
  • Pfizer Investigational Site
    Chennai, Tamil Nadu 600 003, India
  • Pfizer Investigational Site
    Denpasar, Bali, Indonesia
  • Pfizer Investigational Site
    Jakarta, Jakarta Selatan, Indonesia
  • Pfizer Investigational Site
    Jakarta Selatan, Jakarta 10430, Indonesia
  • Pfizer Investigational Site
    Surabaya, Indonesia
  • Pfizer Investigational Site
    Kaunas, 50185, Lithuania
  • Pfizer Investigational Site
    Kaunas, 50425, Lithuania
  • Pfizer Investigational Site
    Klaipeda, 94231, Lithuania
  • Pfizer Investigational Site
    Vilnius, 09112, Lithuania
  • Pfizer Investigational Site
    Acapulco, Guerrero 39670, Mexico
  • Pfizer Investigational Site
    Zapopan, Jalisco 45170, Mexico
  • Pfizer Investigational Site
    Mexico D.F., 14269, Mexico
  • Pfizer Investigational Site
    Khotkovo, Moscow Region, 142601, Russian Federation
  • Pfizer Investigational Site
    Moscow, 107076, Russian Federation
  • Pfizer Investigational Site
    Moscow, 115522, Russian Federation
  • Pfizer Investigational Site
    Moscow, 119021, Russian Federation
  • Pfizer Investigational Site
    Moscow, 125367, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 192019, Russian Federation
  • Pfizer Investigational Site
    Belgrade, 11000, Serbia
  • Pfizer Investigational Site
    Kragujevac, 34000, Serbia
  • Pfizer Investigational Site
    Ljubljana, Slovenia
  • Pfizer Investigational Site
    Langreo, Asturias 33900, Spain
  • Pfizer Investigational Site
    Zamora, 49021, Spain
  • Pfizer Investigational Site
    Istanbul, 34203, Turkey
  • Pfizer Investigational Site
    Kocaeli, 41380, Turkey
09

References and documents

Publications

  • Kasper S, Iglesias-Garcia C, Schweizer E, Wilson J, DuBrava S, Prieto R, Pitman VW, Knapp L. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014 May;17(5):685-95. doi: 10.1017/S1461145713001557. Epub 2013 Dec 19. PubMed 24351233 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2008
First posted
Feb 27, 2008
Start
May 2009
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Apr 19, 2013
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00624780
Responsible party
Sponsor
First posted
Feb 27, 2008
Start date
May 2009
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Apr 19, 2013
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion